LITMUS Changes the Biopsy Calculus: What the Nature Medicine Data Means for Your MASLD Protocol
A Nature Medicine study using the 10,000-patient LITMUS registry shows non-invasive fibrosis tests can replace liver biopsy endpoints. Here's...
Clinical Trial Endpoints
The FDA Measures All Schizophrenia Symptoms at the Same Clock. A Six-Trial IPD Analysis Just Proved That’s Wrong.
A Lancet Psychiatry IPD meta-analysis of six antipsychotic trials shows hostility resolves weeks before negative symptoms—exposing a critical flaw...
The LITMUS Study Just Changed How You Should Design Your MASLD Trial Endpoints
LITMUS Imaging Study validates imaging and serum biomarkers for MASLD fibrosis—here's what it means for endpoint strategy in your...
Obesity Trials Are Optimized to Win Approval, Not to Predict Real-World Use
Nature Medicine's 2026 analysis exposes why obesity drug trials maximizing weight loss endpoints produce results that collapse on contact...
The Trial That Should Rewrite the Rare Disease Playbook — But Probably Won’t
AstraZeneca's Phase 3 benralizumab trial in hypereosinophilic syndrome just delivered one of the cleanest efficacy signals in rare disease...